Clinical trial
Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and…
NCT00143000 · NORDynamIC Study Group, Other · Completed
Key facts
| NCT number | NCT00143000 |
|---|---|
| Title | Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3 |
| Official title | A Multicenter Study Evaluating the Efficacy and Safety of 12 Weeks Versus 24 Weeks Peginterferon Alfa-2a 40KD Combination Therapy With Ribavirin in Interferon Naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection |
| Lead sponsor | NORDynamIC Study Group, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C Virus |
| Intervention type | Drug |
| Interventions | Peginterferon alfa-2a 40KD and Ribavirin |
| Enrollment | 392 |
| Start date | Apr 1, 2004 |
| Completion | Oct 1, 2006 |
| First posted | Sep 2, 2005 |
| Last update posted | Apr 7, 2008 |
| Countries | Sweden |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: